AMSTERDAM, The Netherlands and BARCELONA, Spain, July 15 /PRNewswire-FirstCall/ -- Agendia BV and Ferrer inCode today announced an agreement that will give Ferrer exclusive rights to sell two of Agendia's signature cancer diagnostic services -- MammaPrint(R), a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, and CupPrint*, a gene expression profiling service which offers a fast and reliable method of identifying the primary tumor site in Cancer of Unknown Primary (CUP). Under the exclusive distribution agreement, Ferrer has gained rights to sell the tests in Germany, France, Italy, and Portugal, in addition to a current agreement signed in 2007 covering Spain.
"We are confident that Ferrer inCode is the right partner for the successful expansion of MammaPrint and CupPrint into these additional European markets," said Dr. Bernhard Sixt, president and chief executive officer of Agendia. "This agreement will allow us to increase the availability of our services to more customers in these countries, with the result being that more patients and their physicians will have access to the valuable information provided by these tests."
MammaPrint is a clinically proven, highly accurate gene expression
profiling test that offers healthcare professionals a unique personalized
prognostic analysis to determine a patient's individual risk of recurrence
of breast cancer. MammaPrint, the first In Vitro Diagnostic Multivariate
Index Assay (IVDMIA) to acquire market clearance from the U.S. Food and
Drug Administration (February 2007) provides information that helps
physicians and patients to make more effective treatment decisions, which
may include minimizing the use of chemotherapy, thereby avoiding serious
potential side-effects. CupPrint* is an innovative diagnostic service that
identifies the origin of the primary tumor in Cancer of Unknown Primary,
which accounts for up to five percent of all new cancer refer
|SOURCE Agendia BV|
Copyright©2008 PR Newswire.
All rights reserved